Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 69.0% in June

Bone Biologics Co. (NASDAQ:BBLGGet Free Report) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 21,800 shares, an increase of 69.0% from the May 31st total of 12,900 shares. Approximately 4.2% of the shares of the company are sold short. Based on an average daily trading volume, of 79,700 shares, the short-interest ratio is currently 0.3 days.

Bone Biologics Stock Up 0.7 %

BBLG traded up $0.01 on Friday, hitting $1.22. 31,940 shares of the company’s stock traded hands, compared to its average volume of 93,317. The company’s 50 day simple moving average is $1.60 and its 200-day simple moving average is $2.57. Bone Biologics has a one year low of $1.13 and a one year high of $14.16.

Bone Biologics (NASDAQ:BBLGGet Free Report) last issued its earnings results on Tuesday, May 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.60) by $6.29. Research analysts expect that Bone Biologics will post -5.32 earnings per share for the current fiscal year.

Bone Biologics Company Profile

(Get Free Report)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.

See Also

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with's FREE daily email newsletter.